PTP1B has gained much attention in recent years due to its ability to attenuate insulin signaling and it is currently regarded as a potential therapeutic target against metabolic syndrome, obesity and diabetes. Here, PTPN1 is linked to obesity due to melanocortin 4 receptor deficiency.